Toggle Offcanvas
...
 
Dasatinib Tenders

Dasatinib Tenders

View Dasatinib tenders, RFPs and contracts. Bid on readily available Dasatinib tenders with the best and most comprehensive tendering platform, since 2002.
Dasatinib is a targeted therapy used in chronic myeloid leukemia CML and certain types of acute lymphoblastic leukemia ALL . It works by blocking specific proteins called tyrosine kinases that promote cancer cell growth.

Bidding for Dasatinib tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dasatinib.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dasatinib market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dasatinib tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

13 Live Notices for Dasatinib Tenders

Showing 1 to 13

Delivery Of Medicinal Products
country Poland
posting date20 Aug 2025
deadline24 Sep 2025
Dasatinib (Doe), Purpose (Doe), Bexarothene (Doe), Vanganclovy (Doe) And Methade (Doe)
country Spain
posting date19 Aug 2025
deadline02 Sep 2025
Dasatinib (Doe), Purpose (Doe), Bexarothene (Doe), Vanganclovy (Doe) And Methade (Doe)
country Spain
posting date18 Aug 2025
deadline02 Sep 2025
Dasatinib 100 Mg And 50Mg Agreement For 24 Months
country Chile
posting date06 Aug 2025
deadline05 Sep 2025
Delivery Of Medicinal Products
country Poland
posting date25 Jul 2025
deadline29 Aug 2025
Completion Of Non-Exclusive Discount Agreements According To Section 130A (8) Sgb V On The Active Ingredients Mentioned With A Final Option In The Context Of The So-Called Open House Process.
country Germany
posting date03 Jul 2025
deadline31 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dasatinib (Excl. Strength 100 Mg In Standard Sizes N2 And N3, Atc L01Ea02 For The Period 01.11.24 - 31.10.26
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dasatinib (Excl. Strength 100 Mg In Standard Sizes N2 And N3, Atc L01Ea02 For The Period 01.11.24 - 31.10.26
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Dasatinib 70 Mg Oral Tablet
country India
posting date23 Aug 2025
deadline10 Sep 2025
Tab. Dasatinib 70 Mg.
country India
posting date23 Aug 2025
deadline07 Oct 2025
Tab. Dasatinib 70 Mg.
country India
posting date21 Aug 2025
deadline03 Sep 2025
Tab Dasatinib 100Mg
country India
posting date20 Aug 2025
deadline27 Aug 2025
Tab Dasatinib 100 Mg
country India
posting date20 Aug 2025
deadline01 Sep 2025

Share Share this page